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Summry The proteolytic modification of plasminogen activator inhibitor 2 (PAI-2) was studied during
apoptosis in the human promyelocytic leukaemic NB4 cell line during treatment with the phosphatase
inhibitors okadaic acid and calyculin A as well as the protein synthesis inhibitor cycloheximide. The apoptic
type of cell death was ascertained by morphological and biochemical criteria. In cell homogenates PAI-2 was
probed by ['I1]urokinase plasminogen activator (uPA) and detected as a sodium dodecyl sulphate-stable Mr
80.000 complex after reducing sodium dodecyl sulphate-polyacrylamide gel electrophoresis and autoradio-
graphy. During apoptosis a smaller (IM, 70.000) uPA-PAI-2 complex was consistently detected. The
modification was in the PAI-2 moiety. as the ['2I]uPA tracer could be extracted in its intact form from the
complex. Thus the cleaved PAI-2 isoform is a biochemical marker of apoptosis in the promyelocytic NB4 cell
line. The modified PAI-2 isoform was also detected in homogenates made from purified human mononuclear
leukaemic cells aspirated from the bone marrow of patients suffering from acute and chronic myeloid
leukaemia.
Apoptosis is a fundamental biological process involved in
embryogenesis. morphogenesis. tumour regression and organ
involution (for a recent review see Wyllie. 1993). Since apop-
tosis is a rather scattered phenomenon in intact tissues.
alternative in vitro models have been developed in which
apoptotic cell death can be induced in a larger fraction of the
cell population.
Apoptosis-like cell death has been induced by addition of
cAMP or various cytokines or withdrawal of growth factors
(for a recent review see Schwartzman & Cidlowski. 1993).
Recently the protein phosphatase inhibitors okadaic acid
(OA) and calyculin A have been found to induce apoptosis in
different cell types (Boe et al.. 1991: Ishida et al.. 1992:
Vintermyr et al.. 1993).
PAI-2 is considered a component of the fibrinolytic path-
way. being an efficient inhibitor of tissue-type plasminogen
activator and urokinase plasminogen activator (uPA). It is
principally expressed in monocytes macrophages and tropho-
blasts (Astedt et al.. 1987; Vassalli et al.. 1992). PAI-2 lacks a
normal NH,-terminal signal sequence (Ye et al.. 1987:
Antalis et al.. 1988) and is by facultative translocation pre-
sent as both a cytosolic Mr 43.000 and a secreted M,
60.000-70.000 glycoprotein (Belin et al.. 1989). No intracel-
lular function for the cytosolic PAI-2 has yet been described.
even though it has been shown to be a substrate for the
intracellular enzyme tissue transglutaminase (Jensen et al..
1993. 1994). Yet killing of a fibrosarcoma cell line by tumour
necrosis factor (TNF) was inhibited by superexpression of
the intracellular form of the senine protease inhibitor, plas-
minogen activator inhibitor-2 (PAI-2) (Kumar & Baglioni.
1991). suggesting a possible cytoprotective role as seen in the
antiapoptotic action of the oncogene bcl-2 (Henderson et al..
1991).
The present study was undertaken to determine whether
intracellular PAI-2 is modified or its expression altered dur-
ing in vitro induced apoptosis-like cell death in human pro-
myelocytic leukaemic NB4 cells (de The et al.. 1990: Lanotte
et al., 1991). We report the occurrence of a novel low
molecular weight PAI-2 isoform (Mr -33.000) with intact
uPA-binding affinity in apoptotic NB4 cells. Its expression
was independent of de noso macromolecular biosynthesis.
suggesting specific proteolytic processing of cellular PAI-2
during NB4 cell apoptosis. This suggests that proteolytically
modified intracellular PAI-2 might serve as a biochemical
marker for an apoptosis-associated intracellular proteolytic
activity. In an attempt to evaluate the clinical significance of
this observation we found the cleaved PAI-2 isoform to be
present in leukaemic cells from some patients suffering from
acute and chronic myeloid leukaemia (AML, CML).
Materals and methods
Materials
Low molecular weight urokinase plasminogen activator
(LMW-uPA) was a gift from Dr J. Henkin, Abbott
Laboratories. IL, USA. Recombinant human PAI-2 ex-
pressed in Escherichia coli was a gift from Dr E. Schuiler.
Behringwerke, Germany. Anti-PAI-2 IgG was purified by
protein A affinity chromatography (Pharmacia. Sweden)
from goat serum raised against recombinant PAI-2 kindly
supplied by Dr S.A. Cederholm-Williams, John Radcliffe
Hospital. Oxford, UK. "I51 (carrier free), [32PJdCTP, DNA
multiprime labelling kit and Hybond-N nylon membranes
were purchased from Amersham, UK. OA and calyculin A
were from LC Services Corporation, Woburn. MA. USA.
Dimethylsulphoxide and cycloheximide were from Sigma. St
Louis, MO, USA. The PAI-2 cDNA was a gift from Dr G.
Woodrow. Australia Biotechnology. Australia.
Cell culture
The stable human promyelocytic leukaemiic NB4 cell line
(Lanotte et al.. 1991) was cultured in Dulbecco's
modification of Eagle's medium (Sigma)) supplemented with
10% fetal calf serum (Biochrom. Germany). In all
experiments cells in logarithmic growth were seeded at a
density of 2 x lIW ml i and kept below 5 x l0W ml1 ' during
the experimental period for optimal growth conditions. The
cells were free of mycoplasma and other bacteria. For
analysis cells were collected by centrifugation at 700 g, for
5 min. The cell pellet was immediately processed for DNA
extraction (see below). RNA extraction (see below) or pro-
tein extraction. Protein was extracted by solubilisation in
lysis buffer (120 mmol 1' sodium chlonrde, 50 mmol -'
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HEPES, pH 7.4. 5 mmol 1' EDTA. 3 mmol I` EGTA.
0.05 mg ml-' aprotinin (Behringwerke. Marburg. Germany).
1 mg ml-' soya bean trypsin inhibitor. 2 mmol 1-' phenyl
methyl sulphonyl fluoride (PMSF). 0.5 mmol 1 dithioervth-
ritol. 250 mmol 1' sucrose. 1% Triton X-100 (all from
Sigma. unless noted otherwise) at a concentration of approxi-
mately 1.5 x 10' ml-'. homogenised by three strokes for 5 s
in a Ultra Turrax homogeniser (Janke & Kunkel, Germany).
divided in two tubes and snap frozen in liquid nitrogen. The
samples were stored at - 80C. One tube was used for
['2I]uPA binding experiments and the other for protein deter-
mination by the BioRad protein assay for detergent-
containing samples (BioRad Laboratories, Richmond. CA.
USA).
Patient cells
Pnrmary diagnosis of the patient cell populations was based
on morphological and cytochemical examination (Bennett et
al.. 1985). Mononuclear cells were prepared from sternal
bone marrow cells at the time of diagnosis by density centri-
fugation (Lymphoprep (1.077 gml-', Nycomed, Norway) for
25 min, 2.500 r.p.m. at ambient temperature using a Sigma E
centrifuge. The interphase consisting of mononuclear cells
was washed three times for 10 min at 1,200 r.p.m. in Hanks'
buffered salt solution (Biochrom) and the pellet resuspended
in HEPES-buffered RPMI-1640 (Sigma) containing 20% fetal
calf serum (Biochrom) at a concentration of 1-5 x 10'
cells ml' prior to cryopreservation. Cryopreservation was
performed by supplementing the cell suspensions with 10%
dimethylsulphoxide, freezing at - 8OC for 6 h before transfer
to liquid nitrogen according to Kristensen et al. (1987). All
the procedures prior to freezing were performed between 0°C
and 4°C. except when noted, and the viability at that time
was more than 95% as determined by trypan blue dye ex-
clusion. All cell preparations contained more than 90%
leukaemic cells as evaluated by flow cytometric analysis using
anti-CD13. 14. 15. 33 and 34 monoclonal antibodies. Deter-
gent extracts of the leukaemic cells were made by thawing the
cryopreserved cells on iced water, followed by pelleting and
washing of the cells twice in phosphate-buffered saline by
centrifugation for 10 min at 1.500 r.p.m.. 4'C (Megafuge
1-OR. Heraeus Sepatech. Germany). prior to homogenisation
as described above for the NB4 cells. All human cell samples
for the study were obtained according to the principles ex-
pressed in the Second Helsinki Declaration.
Light microscopy
NB4 cells were sedimented by centrifugation at 1,500 r.p.m.
for 4 mn in a cytocentrifuge (Shandon Scientific, Runcorn.
UK). Specimens were prepared by spray fixation (Cell-Fix,
Shandon Scientific) and staining with May-Grunwald-
Giemsa (Duprez et al., 1993).
Electron nmicroscop!
NB4 cells (3 x 10'cells) were fixed at 37'C in 0.1 mol 1'
sodium cacodylate buffer. pH 7.4. containing 1.5%
glutaraldehyde. and placed on ice for 15 min. The samples
were subsequently rinsed three times in 0.1 M sodium
cacodylate buffer and impregnated in buffer containing 2%
osmium tetroxide for 30 min. The cells were then dehydrated.
embedded in resin. sectioned and stained with uranyl acetate
and lead citrate as previously described (Vintermyr et al..
1989). The specimens were examined in a Jeol IOOCX elec-
tron microscope.
DNA fragmentation assay
DNA was extracted from cell pellets containing 2 x 106 NB4
cells by dissolution in 0.5 ml of cell lysis buffer (100 mmol 1'
EDTA. 10 mmol I' EGTA. 0.5% SDS, 10 mmol I' Tris-
HCI. pH 8.0). and subsequent treatment with 30jig ml-'
RNAse and 100 g mgl-' proteinase K (enzymes purchased
from Boehringer Mannheim, Germany), according to stan-
dard protocols (Sambrook et al.. 1989). Thereafter DNA was
extracted in 10 mmol 1-' Tris-buffered phenol. pH 8.0.
washed twice in 70% ethanol. air dried and redissolved in
10 mmol I` Tris-HCI. 1 mmol 1-' EDTA. pH 7.5. as de-
scribed elsewhere (Duprez et al.. 1993). DNA aliquots (10pg)
were electrophoresed in 1.5% agarose gels and stained in
0.5 jg ml-' ethidium bromide. The degree of chromosomal
degradation was visualised by UV illumination.
mRNA blotting
The pellets of 6 x 106 cells were dissolved in 600;1l
guanidiium thiocyanate in 25 mmol l-1' sodium citrate.
pH 7.4. Total RNA was isolated according to Chomczynski
& Sacchi (1987). Electrophoresis and subsequent blotting of
total RNA onto nylon membranes were essentially as
previously described (Houge et al.. 1990). Hybridisation
using [2P]dCTP random prime labelled human PAI-2 or
A-actin cDNA probes was performed essentially as described
elsewhere (Madsen et al.. 1991). The filters used for PAI-2
blotting were stripped by submersion in boiling 0.1% SDS.
left to cool to ambient temperature and rinsed prior to
incubation with the 32P-labelled A-actin cDNA probe from
Clontech (Palo Alto. CA. USA).
['II]uPA binding experiments
LMW-uPA was labelled with 1251 to a specific activity of
40 mCi mg-', using chloramine-T as oxidising agent (Jensen
et al.. 1990). For binding experiments. detergent extracts of
NB4 cells and mononuclear cells, corresponding to 2.3 x 10'
and 2 x I0 cells respectively, were thawed in iced water.
centrifuged for 10 min. 4'C. at 15.000 r.p.m. (Megafuge LOR.
Heraeus Sepatech, Germany). and the supernatants subse-
quently incubated with approximately 50.000 c.p.m. 2'1I]LMW-uPA for 20 mmn at 0°C. The incubation was ter-
minated b) supplementing to 1% SDS. 20 mmol 1'
dithioerythritol. 20% glycerol. 20 mmol 1-' Tris. pH 6.8. and
heating for 3 min at 95'C. SDS-PAGE was carried out using
continuous 8-16% gradient polyacrylamide gels according to
Jensen et al. (1990). Gels were stained, dried and subjected to
autoradiography using Hyperfilm MP (Amersham. UK).
Active PAI-2 was visualised after the formation of an ap-
proximately AMr 80.000 SDS-stable ['12I]LMW-uPA-inhibitor
complex. complex formation being sensitive to anti-PAI-2
lgG.
Results
Inhibition ofserine threonine protein phosphatases by okadaic
acid or calvculin A induces morphological and biochemical
effects resembling apoptotic cell death
NB4 cells exposed to OA reacted by extensive blebbing of the
plasma membrane and disappearance of microvilli (Figure 1).
Similar morphology was obtained by exposure to calyculin A
(not shown). Treated cells showed extensive condensation of
nuclear chromatin and segregation of subcellular organelles
forming interconnected clusters of membrane-bound
organelles (Figure 1). Lumps of condensed chromatin or
'micronuclei' were frequently observed in the cytoplasm,
especially in cells challenged with calyculin A (not shown).
The morphological appearance of micronuclei was different
from that of chromosomes at mitosis. Although the apop-
totic cells were morphologically deformed, they still excluded
trypan blue (dye exclusion test), suggesting that the integrity
of their plasma membrane remained intact. The transition
time from apparent normal non-condensed to abnormal con-
densed chromatin appeared rather swift, thus rendering very
few cells in the transitional state. In the presence of
316 nmol 1' OA more than 80% of exposed cells were de-
formed within 6 h. demonstrating that these effects could be
induced synchronously and apparently independent of cell836 P.H. JENSEN et al.
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Figre I Morphological effects of OA on human promyelocytic leukaemic NBW cells. Cells were cultured in the absence of (a and
c) or presence (b and d) of 100 nmol 1' OA. Twelve hours after the addition cell aliquots (a and b) were pooled by
cytocentrifugation. spray fixed, stained with May-Gruinwald-Giemsa and viewed in a Zeiss (axiomate) microscope using
differential interference contrast (Nomarski) microscopy. Magnification x 1.300. For ultrastructural studies (c and d) cell aliquots
were processed for transmission electron microscopy as described in the Materials and methods section. Magnification
x 6.000.
cycle phase. On exposure to lower concentrations of OA the
induction of cell death was less synchronous; thus only 50%
of the cells were deformed after a challenge to 100 nmol 1`
OA for 12 h. At lower concentrations of OA an increased
fraction of the cells became apparently arrested in
mitosis.
In the apoptotic cells the synthesis of new proteins was
nearly abolished, whereas in the preapoptotic phase ongoing
protein synthesis was unaffected or slightly up-regulated as
evidenced by [35Sjmethionine pulse labelling of challenged
cells (data not shown). The time courses for induction of
condensation of chromatin and inhibition of protein syn-
thesis were rather similar. OA was about 50- 100 times less
potent than calyculin A for induction of these effects.
Specific degradation of chromosomal DNA was a promi-
nent feature in apoptotic cells challenged with OA or
calyculin A (Figure 2). DNA fragmentation was observed at
calyculin A concentrations 50 to 100-fold lower than OA
concentrations but with less synchrony than OA. Further.
OA induced specific cleavage in the V13 variable region of
28S rRNA (G. Houge. personal communication), as also
recently shown in other apoptotic cells (Houge et al., 1993).
The morphological effects (condensation of chromatin) and
inhibition of protein synthesis preceded chromosomal
fragmentation by 3 h, suggesting that degradation of DNA
was a rather late event in the type of apoptosis induced by
OA and calyculin A in these cells.
Inhibition of protein synthesis by cycloheximide also
induced morphological (not shown) and biochemical (Figure
2. lane 4) characteristics in NB4 cells resembling apoptotic
cell death. To achieve complete inhibition of protein syn-
thesis, cycloheximide at concentrations above 30;Lmol 1 '
must be used. Cycloheximide used in the range 1-30;Lmol 1'
also inhibited ongoing protein synthesis, but did not abolish
it. The apoptotic cell death induced by inhibition of protein
synthesis was much less synchronous than after exposure to
OA.
Cleavage ofintracellular PAI-2 during in vitro-induced
apoptosis
Figure 3 depicts the expression of intracellular PAI-2 activity
during the induction of apoptosis. The PAI-2 assay is based
on the formation of SDS-stable complexes between active
PAI-2 in cell extracts and an "SI-labelled LMW-uPA tracer
containing the catalytic but not the receptor-binding domain.
During control culture PAI-2 is expressed at a steady state
corresponding to the formation of the approximately Mr
80,000 ['251]LMW-uPA-PAI-2 complex shown in Figure 3,
lane 1, after culture for .12 h. However, when apoptosis has
been induced by 12 h incubation by 316 nmol I' OA (lane
2). 3 nmol I` calyculin A (lane 3) or 100iLmol 1-' cyclohexi-
mide (lane 4), a smaller Mr 70,000 ['25I]LMW-uPA-PAI-2
complex appears below the native Mr 80,000 complex. The
identity of the ['VI]LMW-uPA binding inhibitors as non-
glycosylated PAI-2 is based on the following observations:
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Figure 2 OA. calyculin A and cycloheximide induce specific
internucleosomal DNA fragmentation in NB4 cells. Cells were
cultured in the presence of 100 nmol 1 OA (lane 2). 30 nmol I-I
calvculin A (lane 3) or 100;.moll-' cycloheximide (lane 4). or
left unsupplemented (lane I) as a control. After exposure for 12 h
the cells were pooled by centnrfugation and DNA extracted and
subjected to agarose gel electrophoresis. The size of the inter-
nucleosomal DNA fragments was in the range 195-200 bp as
evidenced bv the A-DNA reference marker (lane A).
1. Formation of SDS-stable complexes with a plas-
minogen activator.
2. Co-migration in reducing SDS-PAGE of the Mr
80,000 [1rIluPA-inhibitor complex with uPA com-
plexed with recombinant Mr 43,000 PAI-2 expressed in
E. coli (lane 10).
3. Equal abrogation of the formation of both the high
and low molecular weight ['25luPA-inhibitor complex
by the presence of goat IgG raised against recombinant
PAI-2, but not by preimmune IgG (Figure 3a, lane 9 vs
lane 8). This antiserum has been tested by immuno-
blotting on keratinocyte extracts resolved by
two-dimensional gel electrophoresis and found to be
monospecific for PAI-2 (J. Celis & H.H. Rasmussen,
personal communication).
That the cleavage of PAI-2 should have occurred during
permeabilisation of the cells or during incubation of the cell
extracts with the ["'IjuPA tracer was unlikely since these
procedures were carried out on ice and in presence of pro-
tease inhibitors. Additionally, the cleavage of PAI-2 was only
observed in apoptotic cells and never in normal cells,
although the latter contained a reasonable amount of PAI-2.
Furthermore, when recombinant ["1JPAI-2 was added to
LMW-uPA-PAI-2 -
LIW-uPA -
Fire 3 Effect of in *itro apoptosis and OA on cellular PAI-2
isoforms as detected by ['-'I]LMW-uPA binding. NB4 cell extracts
were incubated with ['21]LMW-uPA tracer and analysed by
reducing 8-16% gradient SDS-PAGE and autoradiography. a.
Cells were incubated for 12 h in the presence of 316 nmol 1` OA
(lane 2). 3 nmol I` calyculin A (lane 3) or 100 iLmol I` cyclohex-
imide (lane 4) and (lane 1. control). Note the appearance of the
smaller approximately 70 kDa uPA-PAI-2 band in the treated
samples. Lanes 5-7 present a time course (9. 12 and 24 h) of
PAI-2 induction and cleavage in the presence of 100 nmol 1`
OA. Anti-PAI-2 IgG-mediated inhibition of uPA-PAI-2 complex
formation (lane 9. as lane 7 but supplemented with 0.5 mg ml-'
anti-human recombinant PAI-2 goat IgG during the LMW-uPA
binding: lane 8. as lane 9 but supplemented with 0.5 mg ml-'
preimmune goat IgG). Lane 10 represents complex formation
between ['251]LMW-uPA and I ng of recombinant human PAI-2.
Bars, indicating Mr 180.000. 96.000. 67.000 and 43.000 respec-
tively. are presented to the left of a and b. b. Companrson of the
'-'1-labelled LMW-uPA tracer dissociated from high and low
molecular weight [''I]uPA-PAI-2 complexes. Pieces of the dried
polyacrylamide gel corresponding to the high and low molecular
weight ['-'luPA-PAI-2 complexes as shown in a. lane 7. were
exised and subjected to ester hydrolysis in I mol 1' hydroxy-
lamine pH II. for 2 at room temperature prior to reducing
SDS-PAGE and autoradiography. Lane 1. native ['"1]LMW-
uPA tracer. Lanes 2 and 3 represent the extracted tracer from the
low and high molecular weight uPA-PAI-2 species respectively.
Lane 4 represents the label extracted from an in vitro formed
LMW-uPA complex with recombinant human PAI-2.
extracts from normal and okadaic acid-treated cells the
recombinant PAI-2 was not cleaved during the time corres-
ponding to the binding of the [(iSIuPA tracer.
That the cleavage of the ['IjuPA-PAI-2 complex could
be in the uPA rather than in the PAI-2 moiety was carefully
addressed in further experiments (Figure 3b). We used the
method of Wun and Reich (1987), rendering the uPA-PAI-2
complexes labile in the presence of the nucleophilic agent
hydroxylamine, thus leaving PAI-2 and uPA with intact
molecular size. Thus, if the uPA moiety of the uPA-PAI-2
complexes was intact, the dissociated [1"ULMW-uPA from
both high and low molecular weight uPA-PAI-2 complexes
should co-migrate during a subsequent reducing SDS-PAGE.
As shown in Figure 3b, both native [1'5]LMW-uPA tracer
(lane 1) and tracer dissociated from the ['251]uPA-PAI-2
complexes of Mr 70,000 (lane 2) and Mr 80,000 (lane 3)
migrated equally in the SDS gel. Also the tracer from com-
plexes formed in vitro between ['"I]LMW-uPA and recom-
binant PAI-2 (Figure 3b, lane 4) co-migrated with the tracer
from the low molecular weight complex on the gel.
A major task was to test whether the specific cleavage of
PAI-2 was an essential event in apoptotic cells or more a
secondary event caused by the intrusion of extracellular pro-
teases. Firstly, both normal and apoptotic cells excluded
I I I I
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trypan blue. suggesting that the plasma membrane was intact
in the apoptotic cells. Secondly, the membrane permeability
was further tested by adding the M, 33,000 ['"5flLMW-uPA
to the extracellular environment. No uPA-PAI-2 complexes
were observed when the ['"I]LMW-uPA tracer was added to
the medium during the last 15 min of the culture. In these
experiments the activity of the tracer was blocked by addi-
tion of the serine protease inhibitor, PMSF, prior to
permeabilisation of the cell membrane by Triton X-100. In
contrast complexes did form if PMSF was not added or
added 10min after permeabilisation of the membrane (not
shown). In further experiments the effect of extracellular
plasmin was tested more specifically. In these trials the serine
protease inhibitor. aprotimnn (10 g ml'). was added to cells
in absence or presence of okadaic acid. However, the
cleavage of PAI-2 was not inhibited by the presence of
aprotimn, suggesting that plasmin did not cause the split in
PAI-2. These above results support the view that the specific
cleavage of PAI-2 is a genuine intracellular event that occurs
during induction of apoptotic cell death in human myeloid
cells.
In order to optimise the generation of the cleaved PAI-2
isoform, we studied the time and concentration dependency
of OA on PAI-2 expression and on formation of the low
molecular weight PAI-2 as OA increases PAI-2 gene expres-
sion in some myeloid cell lines (Medcalf, 1992). Figure 4
shows a Northern blot of purified total RNA hybridised with
a 3'2P-labelled PAI-2 cDNA probe (upper panel). In cells
exposed to 100 nmol 1' OA, a transient but several-fold
increment of the PAI-2 mRNA expression was induced. Peak
expression was noted after 12 h exposure to 100 nmol I` OA
(lane 4). The expression of PAI-2 mRNA was very low in
control cells (Figure 4, lane 1). but could be detected upon
prolonged exposure of the film (not shown). However, in
both normal and OA-induced cells only one PAI-2 transcnrpt
and of equal size (1.8 kb) was found, excluding the possibility
that a smaller PAI-2 transcript could be induced during
apoptosis by OA. In the presence of 316 nmol I' OA the
PAI-2 mRNA expression occurred earlier, but remained
weaker and was not detected at time points later than 6 h
from time of exposure (data not shown). The equal loading
of mRNA was ascertained by the nearly constant signal
when using a A-actin cDNA probe on the same filter (Figure
4. lower panel). OA (100 nmol 1`) caused at the protein level
an increase in the amount of active intracellular PAI-2 from
9 h and later (Figure 3, lanes 5-7). The PAI-2 cleavage first
became detectable by 12 h with more than 50% of the active
PAI-2 cleaved at 24 h. Higher (316 nmol 1`) or lower
(10 nmol 1- ) concentrations of OA did not result in more of
the cleaved PAI-2 form (not shown). Thus. an optimal
system for the generation of cleaved PAI-2 and, accordingly.
the in vitro apoptosis-associated protease activity is
represented by the culture of NB4 cells for 24 h in the
presence of l00nmoll I OA.
PAI-2 cleavage in mveloid leukaemic bone marrow cells
In order to search for potential clinical relevance of the low
Mr PAI-2 isoform observed during in vitro apoptosis, we
screened different types of human myeloid leukaemia cells. In
some cell homogenates of myeloid leukaemic cells isolated
from the bone marrow of patients suffering from acute and
chronic myeloid leukaemia, the cleaved PAI-2 variant was
noticed (Figure 5, lane I vs lanes 2-5). The leukaemic cells
were viable as judged by trypan blue exclusion before
homogenisation. The lack of PAI-2 cleavage in the control
monocytes is in agreement with previous studies using this
technique (for a review see Vassalli et al.. 1992). Table I
shows the prevalence of PAI-2 cleavage observed among
some patients suffering from AML, AMML and CML. The
low-Mr PAI-2 isoform was more frequently recognised
among the CML patients than among the AML patients.
The number of patient specimens examined so far does not
allow complete statistical analysis.
1 2 3 4 5
1.8 kb-
1.8 kb
Fugue 4 PAI-2 gene expression in okadaic acid (OA)-stimulated
NB4 cells. Northern blot analysis of total RNA (10 ig) extracted
from NB4 cells stimulated with 100 nmol 1-' OA for 0 (control).
6. 9. 12 and 24 h (lanes 1-5 respectively). The filters were probed
with 3P-labelled PAI-2 cDNA (upper panel) or P-actin cDNA
(lower panel). The localisation of the 1.8 kb marker to the left
was extrapolated from the localisations of the ribosomal 28S and
18S bands.
2 3 5
Fugwe 5 Detection of proteolytically modified PAI-2 in human
myeloid leukaemic cells isolated from sternal aspirates. Intracel-
lular PAI-2 was probed by ['251LMW-uPA binding to cell homo-
genates. Lane 1, healthy control; lane 2. AMML; lanes 3 and 4.
AML; lane 5. CML. The bars to the left represents the localisa-
tion of LMW-uPA (bottom) and LMW-uPA-PAI-2 (top).
Table I The presence of cleaved PAI-2 in detergent extracts of
mononuclear bone marrow cells from patients with myeloid
leukaemia
Diagnosis n PAI-2 cleavage
AML 8 3
AMML 3 3
CML 12 9
Control 6 0
apositive cases were defined as having a clear low molecular weight
uPA-PAI-2 complex band. as described in Figure 3. using an
exposure time providing separation of the M, 70.000 and M, 80.000
bands.
Micussio
Intracellular processing of PAI-2 during apoptosis has not
previously been described. The increase in the electrophoretic
migration of the ['25I]uPA-PAI-2 complexes was caused by
modification of the PAI-2 moiety. as the ['25I]uPA tracer
remained unchanged (Figure 2b). Increased migration during
reducing SDS-PAGE could be due to restraints to denatura-
tion caused by intramolecular cross-links between glutamine
and lysine residues as catalysed by transglutaminase rather
than a decreased molecular mass. Transglutaminase activa-
tion has indeed be associated with cellular apoptosis (Fesus
et al., 1989). and we recently showed PAI-2 to be a substrate
for transglutaminase (Jensen et al., 1993. 1994). Nonetheless,
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2 is unlikely for two reasons. First. transglutaminase activity
in the NB4 cells harvested during control culture and apop-
tosis was very low as measured by [H]putrescine incorpora-
tion into casein and not increased during the induction of
apoptosis. Furthermore. no tissue transglutaminase mRNA
could be detected by Northern blotting (P.H. Jensen & O.K.
Vintermyr. unpublished results). Second. we never observed
any diminished apparent size of PAI-2 when incubated with
transglutaminase during the characterisation of PAI-2 as a
substrate for transglutaminase (Jensen et al., 1993. 1994).
Thus the modification of PAI-2 during apoptosis is probably
a proteolytic nature. as recently described for the nuclear
enzyme poly(ADP-ribose)polymerase by Kaufmann et al.
(1993), who also found that de novo protein synthesis was not
required for the proteolysis. The proteolytic cleavage, reduc-
ing the Mr of PAI-2 by 10,000. must be in the N-terminal
third of the molecule since the inhibitor still is functionally
active and its plasminogen activator binding site is located at
the very C-terminal part of the molecule (Huber & Carrell.
1989). Even though internucleosomal degradation of DNA
during apoptosis has been recognised for a long time, the
degradation of other macromolecules as proteins and specific
cleavage of ribosomal RNA (Houge et al., 1993) have not
been well described until recently. Apoptosis-associated pro-
teolvsis has been suggested by various experimental systems.
First, dye binding to proteins in cells (Bruno et al., 1992) or
cell extracts (Kaufmann. 1989) during apoptosis is decreased.
It is recognised. however, that this does not necessarily
indicate an increased proteolysis but could equally reflect an
arrest of protein synthesis with a continuing 'normal' rate of
protein degradation. Second. synthetic proteinase inhibitors
have been reported to arrest the apoptotic cell killing and
DNA fragmentation (Bruno et al., 1992; Gorczyca et al.,
1992: Kaufmann et al., 1993). Third, Yuan et al. (1993) has
recently shown that the mammalian homologue of the
C. elegans apoptosis gene ced-3 is the protease interleukin
11a-converting enzyme, and overexpression of this gene causes
apoptosis in mammalian cells (Miura et al.. 1993). However.
our observation on PAI-2 cleavage in leukaemic bone mar-
row cells is to our knowledge the first demonstration of a
specific proteolytic cleavage for putative apoptosis-associated
proteases in human pathological specimens.
Regarding the interpretation of the clinical results, where
sample treatment might be less rigorous we tested whether
necrosis might produce the PAI-2 cleavage. NB4 cells were
incubated in the presence of increasing concentrations of
saponin or digitonin or simply incubated at room tempera-
ture until they became trypan blue positive. In these circum-
stances no PAI-2 cleavage occurred (data not shown).
Whether the senine protease inhibitor PAI-2 can inhibit
any of the putative apoptosis-associated proteinases remains
to be determined. It is interesting that PAI-2 shows
homology with the cowpox virus gene product crmA. Which
is able to inhibit the action of the apoptotic proteinase
interleukin 1 -converting enzyme. It should be noted that
Asp is the putative (PI) amino acid in the cleavage site of
interleukin 1p and crmA, whereas the PI-residue in PAI-2 is
an Arg residue (Ray et al.. 1992). This indicates a different
proteinase inhibitory specificity of PAI-2 and crmA.
A possible cytoprotective role of PAI-2 during cellular
events of stress has been suggested by the study of Kumar
and Baglioni (1991). in which hyperexpression of PAI-2 pro-
tects a transfected fibrosarcoma cell line against TNF-
mediated cytotoxicitv. Whether the TNF-mediated cellular
killing in this particular study resulted in apoptosis was not
determined. although TNF mediates apoptosis in several
model systems (Gerschenson & Rotello, 1992). Interestingly.
we found that the increase in cytosolic cleaved PAI-2 in the
presence of 100 nmol 1' OA (Figure 3) was somewhat de-
layed compared with the expression of PAI-2 mRNA (Figure
4). the latter more closely reflecting the initiation of apoptotic
morphology (Figure 1). Thus PAI-2 cleavage might mirror
the macromolecular breakdown exemplified by DNA frag-
mentation. gross proteolysis (Kaufmann. 1989) and rRNA
fragmentation (Houge et al.. 1993). rather than represent an
active regulatory step in apoptosis.
Recent enzyme-linked immunosorbent assay studies show
that PAI-2 levels in serum (Scherrer et al., 1991) and cell
homogenates (Wada et al., 1993) can be used as a marker for
myeloid leukaemia and in the differentiation between
different stages of the leukaemia. The existence of cleaved
PAI-2 in some but not all samples from patients suffering
from AML and CML (Table I) might further assist the
subclassification of these leukaemias. The importance of cell
death-suppressor genes, e.g. bcl-2, and tumour suppressor
genes, e.g. p53, the latter in certain situations acting to
induce apoptosis, is well established (for a review see Carson
& Ribeiro, 1993). Thus, as the in vitro observations point to
the cleaved PAI-2 isoform as a marker for apoptosis. we
have initiated studies on the significance of PAI-2 cleavage in
myeloid leukaemia in relation to classical apoptosis markers
as well as prognosis and response to chemotherapy.
The specific site of proteolysis in PAI-2 has not yet been
determined and could be different in the various leukaemic
cells and during in vitro NB4 cell apoptosis. as different
proteinases could be involved. Notwithstanding this cau-
tionary note, the discovery of PAI-2 and poly(ADP-ribose)
polymerase (Kaufmann et al., 1993) as specific substrates for
intracellular apoptosis-associated protease activity raises
several questions. What is the nature of the proteinases
(senine. cysteine, metallo- or aspartic proteinases)? What are
the substrate specifities? Is there expression of a specific
protease during apoptosis, e.g. interleukin la-converting
enzyme, or is merely a dormant protease activated during
this process? Finally, is the observed protease activity of
importance for the process of apoptosis or simply a side-
effect? These questions will require effort to answer but
should be of general importance in cell biology and
oncology.
Abbreviado: AML, acute myeloid leukaemia; AMML, acute
myelomonocytic leukaemia; CML, chronic myeloid leukaemia;
LMW-uPA, low molecular weight urokinase plasminogen activator;
OK, okadaic acid; PAGE, polyacrylamide gel electrophoresis; PAI-2,
plasminogen activator inhibitor 2; SDS, sodium dodecyl sulphate;
uPA, urokinase plasminogen activator.
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